Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2004-11-15
2010-06-08
Hui, San-Ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S422000, C514S012200
Reexamination Certificate
active
07731947
ABSTRACT:
A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.
REFERENCES:
patent: 4111201 (1978-09-01), Theeuwes
patent: 4743449 (1988-05-01), Yoshida et al.
patent: 5091188 (1992-02-01), Haynes
patent: 5278151 (1994-01-01), Korb et al.
patent: 5324280 (1994-06-01), Wong et al.
patent: 5660858 (1997-08-01), Parikh et al.
patent: 5728396 (1998-03-01), Peery et al.
patent: 5904935 (1999-05-01), Eckenhoff et al.
patent: 5932547 (1999-08-01), Stevenson et al.
patent: 5972370 (1999-10-01), Eckenhoff et al.
patent: 5997527 (1999-12-01), Gumucio et al.
patent: 6022561 (2000-02-01), Carlsson et al.
patent: 6113938 (2000-09-01), Chen et al.
patent: 6124261 (2000-09-01), Stevenson et al.
patent: 6130200 (2000-10-01), Brodbeck et al.
patent: 6132420 (2000-10-01), Dionne et al.
patent: 6133429 (2000-10-01), Davis et al.
patent: 6174547 (2001-01-01), Dong et al.
patent: 6235712 (2001-05-01), Stevenson et al.
patent: 6258377 (2001-07-01), New et al.
patent: 6270787 (2001-08-01), Ayer
patent: 6287295 (2001-09-01), Chen et al.
patent: 6331311 (2001-12-01), Brodbeck et al.
patent: 6375978 (2002-04-01), Kleiner et al.
patent: 6419952 (2002-07-01), Wong et al.
patent: 6433144 (2002-08-01), Morris et al.
patent: 6461605 (2002-10-01), Cutler et al.
patent: 6468961 (2002-10-01), Brodbeck et al.
patent: 6485706 (2002-11-01), McCoy et al.
patent: 6508808 (2003-01-01), Carr et al.
patent: 6524305 (2003-02-01), Peterson et al.
patent: 6544252 (2003-04-01), Theeuwes et al.
patent: 6551613 (2003-04-01), Dong et al.
patent: 6673767 (2004-01-01), Brodbeck et al.
patent: 6939556 (2005-09-01), Lautenbach
patent: 7014636 (2006-03-01), Gilbert
patent: 7074423 (2006-07-01), Fereira et al.
patent: 7163688 (2007-01-01), Peery et al.
patent: 7207982 (2007-04-01), Dionne et al.
patent: 7258869 (2007-08-01), Berry et al.
patent: 2003/0059376 (2003-03-01), Libbey, III et al.
patent: 2004/0224903 (2004-11-01), Berry et al.
patent: 2005/0008661 (2005-01-01), Fereira et al.
patent: 2005/0112188 (2005-05-01), Eliaz et al.
patent: 2005/0175701 (2005-08-01), Pan et al.
patent: 2005/0266087 (2005-12-01), Junnarkar et al.
patent: 2005/0276856 (2005-12-01), Fereira et al.
patent: 2006/0193918 (2006-08-01), Rohloff et al.
patent: 2006/0216242 (2006-09-01), Rohloff et al.
patent: 2006/0246138 (2006-11-01), Rohloff et al.
patent: 2007/0027105 (2007-02-01), Junnarkar et al.
patent: 2007/0281024 (2007-12-01), Lautenbach et al.
patent: 0 729 747 (1997-05-01), None
patent: 0 771 817 (1997-05-01), None
patent: 9-241153 (1997-09-01), None
patent: 11-100353 (1999-04-01), None
patent: WO 93/06819 (1993-04-01), None
patent: WO 97/15289 (1997-05-01), None
patent: WO 97/46204 (1997-12-01), None
patent: WO 98/32463 (1998-07-01), None
patent: WO 98/47487 (1998-10-01), None
patent: WO 99/16419 (1999-04-01), None
patent: WO 99/39700 (1999-08-01), None
patent: WO 00/45790 (2000-08-01), None
patent: WO 00/67728 (2000-11-01), None
patent: WO 02/45752 (2002-06-01), None
patent: WO 02/069983 (2002-09-01), None
patent: WO 03/053400 (2003-07-01), None
U.S. Appl. No. 11/347,601, filed Feb. 2006, Dennis et al.
Chaumeil JC, “Micronization: A Method of Improving the Bioavailability of Poorly Soluble Drugs,” Methods and Findings in Experimental and Clinical Pharmacology, Apr. 1998, 20(3), 211-215.
Bakan, D. et al., “Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography”,Journal of Pharmaceutical Science, 1996, 85(9), 908-914.
Cantor, R.S., “Theory of Lipid Monolayers Comprised of Mixtures of Flexible and Stiff Amphiphiles in Anthermal Solvents: Fluid Phase Coexistence”,The Journal of Chemical Physics, 1996, 104(20), 8082-8095.
Chapman, D. et al., “Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins)”,Chemistry and Physics of Lipids, 1967, 1(5), 445-475.
Felker, T.E. et al., “The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling NascentTriglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface”,The Journal of Nutritional Biochemistry, 1993, 4(1), 630-634.
Kabalnov, A. et al, “Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability”,Journal of Colloid and Interface Science, 1996, 184(1), 227-235.
Kabalnov, A. et al., “Macroemulsion Type and Stability of Alkane-Water-Phospholipid Systems”,Book of Abstracts, 210thACS National Meeting, Chicago, Il, Aug. 20-24, 1995, Issue Pt 1.
Massey, John B., “Interaction of Vitamin E with Saturated Phospholipid Bilayers”,Biochemical and Biophysical Research Communications, 1982, 106(3), 842-847.
Wang, X. et al., “Preferential Interaction of α-tocopherol with Phosphatidylcholines in Mixed Aqueous Dispersions of Phosphatidylcholine and Phosphatidylethanolamine”,European Journal of Biochemistry, 2000, 267(21), 6362-6368.
Wang, X. et al., “Ripple Phases Induced by α-Tocopherol in Saturated Diacylphosphatidylcholines”,Archives of Biochemistry and Biophysics, 2000, 377(2), 304-314.
Wang, X.Y. et al., “The Distribution of α-Tocopherol in Mixed Aqueous Dispersions of Phosphatidylcholine and Phosphattidylethanolamine”,Biochimica et Biophysica Acta-Biomembranes, 2000, 1509(1-2), 361-372.
Jain, R.A. et al., “Controlled Delivery of Drugs from a Novel Injectable in Situ Formed Biodegradable PLGA Microsphere System”,Journal of Microencapsulation, 2000, 17(3), 343-362.
Fujii, M. et al., “Effect ofphosphatidylcholineon Skin Permeation of Indomethacin fromgelprepared with Liquid Paraffin and Hydrogenated Phospholipid”,International Journal of Pharmaceutics, 2001, 222(1), 57-64.
Fujii, M. et al., Enhancement of Skin Permeation of Miconazole by Phospholipid and Dodecyl 2-(N, N-dimethylamino) Propionate (DDAIP),International Journal of Pharmaceutics, 2002, 234(1-2), 121-128.
Schmalfuβ, U. et al., “Modification of Drug Penetration into Human Skin Using Microemulsions”,Journal of Controlled Release, 1997, 46(3), 279-285.
Erõs, I. et al., “Multiple Phase Emulsions as Controlled Drug Delivery Therapeutic Systems”,Proc.-Conf. Colloid Chem., 1993, 6thMeeting Date, 193-196.
Nordén, T.P. et al., “Physicochemical Characterization of a Drug-Containing Phospholipid-Stabilized o/w Emulsion for Intravenous Administration”,European Journal of Pharmaceutical Sciences, 2001, 13(4), 393-401.
Bakhtiar, C. et al, Taking Delivery. (Ingredients: Liposomes). (liposomes in cosmetic delivery systems),Soap Perfumery&Cosmetics, 2003, 76(3), 59(4).
Das, S. et al., “Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues”,BioPharm, Nov. 1999, 12(11), 44.
Larsson, K., “Stability of Emulsions Formed by Polar Lipids”,Progress in the Chemistry of Fats and Other Lipids, 1978, 16, 163-169.
Ortiz, A. et al., A Differential Scanning Calorimetry Study of the Interaction of α-Tocopherolwith Mixtures of Phospholipids,Biochim et Biophys Acta, 1987, 898(2), 214-222.
Lundberg, B.., “A Submicron Lipid Emulsion Coated with Amphipathic Polyethylene Glycol for Parenteral Administration of Paclitaxel (Taxol)”,The Journal of Pharmacy and Pharmacology, 1997, 49(1), 16-21.
Hodoshima, N. et al., “Lipid Nanoparticles for Delivering Antitumor Drugs”,International Journal of Pharmaceutics, 1997, 146(1), 81-92.
Quintanar Guerrero D. et al., “Applications of the Ion-Pair Concept to Hydrophilic Substances with Special Emphasis on Peptides”,Pharmaceutical Research, 1997, 14(2), 119-127.
Bauer, K.H. et al., “Non-AqueousEmulsions as Vehicles for Capsule Fillings
Eliaz Rom Ezer
Junnarkar Gunjan
Rohloff Catherine Manya
Weeks Eric William
Zhang Yuanpeng
Fabian Gary R.
Hui San-Ming
Intarcia Therapeutics, Inc.
McClung Barbara G.
Zarek Paul
LandOfFree
Composition and dosage form comprising an interferon... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and dosage form comprising an interferon..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and dosage form comprising an interferon... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4217676